Widely used drug could offer substantial relief to people with chronic cough

August 27, 2012

New research published Online First in the Lancet is the first to show that gabapentin, a drug widely used to treat pain and seizures, substantially reduces the frequency and severity of coughing and other symptoms associated with the extremely common and difficult-to-treat problem of long-term chronic cough.

"These effects are very promising and raise hope for many people with refractory chronic cough—a condition that can be both psychologically and physically disabling and for which no effective drugs are available—who now have a potential new ", says Nicole Ryan from The University of Newcastle in Australia who led the research.

Chronic cough is an increasing clinical problem that currently affects 11% of the population. The precise cause of cough is not known, but research suggests it might be related to central sensitisation which is also implicated in neuropathic pain. has shown a robust effect on chronic neuropathic pain and as such could have a similar effect in people with chronic cough, but until now, no randomised studies have been done.

In this study, 62 patients with refractory chronic cough (a cough lasting 8 weeks or longer) who had not responded to standard treatment were recruited from an outpatient clinic in Australia and randomly assigned to either gabapentin (maximum tolerable daily dose 1800 mg) or placebo for 10 weeks.

Patients returned to the clinic five times to give a rating of their cough using the Leicester cough questionnaire (LCQ) that assigns a score based on physical, social, and of the cough, and to assess cough frequency and severity.

Overall, gabapentin had a significant and sustained improvement on cough-specific quality of life, cough severity, and cough frequency compared with placebo.

After 8 weeks of treatment, significantly more coughers in the gabapentin group reported an improvement in LCQ score of greater than 1.3 (the smallest change in score considered as clinically meaningful) compared with the placebo group (74% vs 46%).

The authors point out that these beneficial effects were not sustained after treatment was stopped adding that, "the reduction in efficacy of gabapentin after withdrawal further supports its antitussive [cough suppressant] effect."

Gabapentin was generally well-tolerated, with less than a third of patients given gabapentin experiencing side-effects (the most common being nausea and fatigue), that were managed by reducing the dose.

According to Ryan, "Gabapentin is effective, well tolerated, and has few drug interactions and therefore its addition to chronic cough standard practice guidelines should be considered, although replication studies are necessary before this happens."

In a linked Comment, Kian Fan Chung from Imperial College, London, UK says, "These results suggest that gabapentin is worth trying in patients with refractory and should provide the impetus to pursue similar trials of other drugs developed to suppress cough sensitisation pathways or target primary afferent nerves associated with cough."

Explore further: Cough may warn of danger for patients with lung-scarring disease

More information: www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60776-4/abstract

Related Stories

Recommended for you

The 'love hormone' may quiet tinnitus

September 23, 2016

(HealthDay)—People suffering from chronic ringing in the ears—called tinnitus—may find some relief by spraying the hormone oxytocin in their nose, a small initial study by Brazilian researchers suggests.

Bile acid uptake inhibitor prevents NASH / fatty liver in mice

September 21, 2016

Drugs that interfere with bile acid recycling can prevent several aspects of NASH (nonalcoholic steatohepatitis) in mice fed a high-fat diet, scientists from Emory University School of Medicine and Children's Healthcare of ...

New therapeutic target for Crohn's disease

September 20, 2016

Research from the Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies a promising new target for future drugs to treat inflammatory bowel disease (IBD). The study, published today in Cell Reports, also indicates ...

Mosquitoes, Zika and biotech regulation

September 19, 2016

In a new Policy Forum article in Science, NC State professor Jennifer Kuzma argues that federal authorities are missing an opportunity to revise outdated regulatory processes not fit for modern innovations in biotechnology, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.